Abstract library

2095 results for "neuroendocrine carcinomas".
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
#733 Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas
Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Marco Volante
#2074 The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study
Introduction: It has been suggested that secondary primary colorectal adenocarcinomas (SPCA) occur more often than normal in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Student Tobias Stemann Lau
#1243 Neuroendocrine Carcinomas of the Prostate
Introduction: Since focal neuroendocrine (NE) differentiation in prostate carcinomas represents a frequent phenomenon when NE markers are used for documentation, NE carcinomas are extremely rare form of highly aggressive prostate tumors.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Pathology, grading, staging
Presenting Author: Professor Alis Dema
Authors: Dema A, Taban S, Anderco D, Bardan R, ...
#2855 Whole Exome Sequencing Reveals the Monoclonal Origin of Gastric Mixed Adenoneuroendocrine Carcinomas
Introduction: Gastric mixed adenoneuroendocrine carcinomas (g-MANECs) are rare neoplasms consisting of adenocarcinoma and neuroendocrine neoplastic components. G-MANECs show more malignant characteristics than gastric adenocarcinomas, while molecular mechanisms underlying the co-existence of the two components remains unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: M.D. Shida Yan
Authors: Yan S, Chen X, Zhang R, Song L, ...
#1087 Gastro-Entero-Pancreatic Mixed Adenoneuroendocrine Tumors. Report of Four Cases.
Introduction: Mixed adenoneuroendocrine carcinomas (MANECs) is an uncommon entity with ill-defined clinicopathologic characteristics.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Pathology, grading, staging
Presenting Author: Georgia Karayannopoulou
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Franziska Briest
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen